Pre-clinical evidence continues to justify PRAME and SLC45A2 as preferential targets: PRAME is over-expressed in approximately half of metastatic UMs and can be eradicated by PRAME-specific T cells in vitro [41], while SLC45A2-directed TCRs show potent, highly selective lysis of UM cell lines with negligible off-tumor cross-reactivity [41]. This evidence concerns the gene SLC45A2 and neoplasm.